Multiple myeloma (MM) is a B-cell malignancy characterized ... As the distribution of the clinical parameters and the percentage of MYC staining cells was not statistically different between ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

Here Dr. Usmani discusses the current outlook for the disease and his vision for developing new treatment approaches at MSK that will improve multiple myeloma prognosis (outcome). This includes very ...

Multiple myeloma (MM) is an incurable malignancy of bone marrow plasma cells characterized by wide clinical and molecular heterogeneity. In this study we applied an integrative network biology ...

There are three stages of multiple myeloma, and the stage you receive at diagnosis gives an overall picture of how far the disease has progressed and helps inform treatment decisions. Your ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Usmani said. “The CEPHEUS results also add further validity to using MRD negativity as an accelerated approval endpoint for predicting PFS outcomes in newly diagnosed multiple myeloma.” Dr. Usmani ...